OCGN (Ocugen) Float Percentage Of Total Shares Outstanding : 97.97% (As of Mar. 17, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Ocugen Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ocugen's float shares is 286.08 Mil. Ocugen's total shares outstanding is 292.01 Mil. Ocugen's float percentage of total shares outstanding is 97.97%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ocugen's Insider Ownership is 1.36%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ocugen's Institutional Ownership is 24.56%.

Ocugen Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Ocugen's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	286.08	/	292.01
	=	97.97%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocugen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (NAS:OCGN) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

OCGN:Mexico 2H51:Germany

Address

11 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.ocugen.com

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Executives

Prabhavathi Fernandes	director	114 MILTON AVENUE, CHAPEL HILL NC 27514
Kirsten Castillo	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Junge Zhang	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Quan Anh Vu	officer: CFO/CBO	22616 ERWIN STREET, WOODLAND HILLS CA 91367
Shankar Musunuri	director, officer: Chief Executive Officer	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Arun Upadhyay	officer: Chief Scientific Officer	C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355
Ramesh Kumar	director	375 PHEASANT RUN, NEWTOWN PA 18940
Uday Kompella	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Marna C Whittington	director	2959 BARLEY MILL ROAD, YORKLYN DE 19736
Jessica Crespo	officer: CAO/SVP, Finance	C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355
Sanjay Subramanian	officer: Chief Financial Officer	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Manish Potti	director	C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355
Vijay Tammara	officer: Vice President	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Suha Taspolatoglu	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Kelly Beck	officer: Vice President	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355